Previous work characterising the genome of neoadjuvant treatment HER2+ breast cancer has demonstrated that mutations in known cancer driver genes such as PIK3CA14,18,19, the immune response20 and the HER2-enriched mRNA intrinsic molecular subtype may all have a role in predicting treatment response5,11,15,17,21. Here, ERBB2 is linked to cancer.